# | DiHAa | Diagnostic category / health problem | Author (year) | LoEb (trial design) | Number of trial participants randomised (IG, CG) | Intervention in the experimental arm | Intervention in the control arm | Follow-up (planned, max, in months) | Reported outcomes | |
---|---|---|---|---|---|---|---|---|---|---|
Medical outcomes | Patient-centred structural and procedural outcomes | |||||||||
1 | deprexis | Mental disorder / depression | Ib (RCT) | N = 1.013 (IG = 509, CG = 504) | Guidedc Web-based intervention (Deprexis) | Care as usual | 6 | Primary: depressive symptom severity measured by PHQ-9; Secondary: severity of depression, psychiatric diagnoses, acute suicidality measured by HDRS-24, QIDS-C16, PHQ-9; quality of life measured by SF-12 | ||
Mental disorder / depression | Meyer et al. (2015) [31] | Ib (RCT) | N = 163 (IG = 78, CG = 85) | Unguidedd Web-based intervention (Deprexis) | Waitlist | 6 | Primary: depressive symptom severity measured by PHQ-9; Secondary: anxiety symptoms, somatic complaints measured by GAD-7, PHQ-15; quality of life measured by SF-12 | |||
Mental disorder / depression | Berger et al. (2011) [32] | Ib (RCT) | N= 76 (IG1 = 25; IG2=25, CG = 26) | Unguided Web-based intervention (Deprexis); guided Web-based intervention (Deprexis) | Waitlist | 6 | Primary: depressive symptom severity measured by BDI-II; Secondary: psychological symptoms measured by 53-item BSI; interpersonal problems measured by IIP; quality of life measured by WHOQOL-BREF | |||
Mental disorder / depression | Moritz et al., (2012) [26] | Ib (RCT) | N = 210 (IG = 105, CG = 105) | Unguided web-based intervention (Deprexis) | Waitlist | NA | Primary: depressive symptom severity measured by BDI; Secondary: acute suicidality measured by DAS, RSE, SBQ-R; quality of life measured by WHOQOL-BREF | |||
2 | elevida | Nervous system / multiple sclerosis | Pöttgen et al. (2018) [33] | Ib (RCT) | N = 275 (IG = 139, CG = 136) | Unguided web-based intervention (elevida) | Waitlist | 6 | Primary: severity of physical and mental fatigue measured by Chalder Fatigue Scale; Secondary: MS-specific motor and cognitive fatigue, anxiety and depression, quality of life, self-reported cognitive difficulties, activities of daily living measured by FSMC, HADS-A and HADS-D, HAQUAMS, MSNQ | |
3 | HelloBetter Diabetes und Depression | Hormones and metabolism / diabetes mellitus, type 1 and 2 | Ib (RCT) | N = 260 (IG = 130, CG = 130) | Guided web- and mobile-based self-help intervention (GET.ON Mood Enhancer Diabetes) | Online unguided psychoeducation Program for depression | 1 | Primary: depressive symptom severity measured by CES-D; Secondary: behavioural activation, problem solving, worry, diabetes-related emotional stress, quality of life measured by HADS, PAID, AADQ, DSMQ, CSQ-8 | ||
4 | HelloBetter Stress und Burnout | Other / difficulties in coping with life | Heber et al. (2016) [36] | Ib (RCT) | N = 264 (IG = 132, CG = 132) | Guided web- and mobile-based training (GET.ON Stress) | Waitlist | 12 | Primary: stress exposure measured by PSS-10; Secondary: depressive symptoms, anxiety symptoms, emotional exhaustion, sleep (severity of insomniac symptoms), work engagement, self-assessment of emotional competencies, psychological distancing from work, worries measured by CES-D, ISI, HADS-A, PSWQ-PW, SF-12, UWES, REQ-PD, TiC-P-G, ERSQ-27, ERSQ-ES-GD, CSQ-8 | |
5 | HelloBetter Vaginismus Plus | Mental disorder / non-organic vaginismus | Ib (RCT) | N = 200 (IG = 100, CG = 100) | Guided web-based intervention (eHealth platform) | Waitlist | 6 | Primary: improvement of vaginal penetration during sexual intercourse measured by PEQ; Secondary: non-coital vaginal penetration ability, sexual functioning, sexuality-related anxiety, penetration-related cognitions measured by PEQ, FSFI, FSQ, VPCQ | ||
6 | Kalmeda | Ears / tinnitus | In publication processe | Ib (RCT) | N = 187 | Mobile-app “Kalmeda” | Waitlist | 3 | Primary: tinnitus exposure measured by mini-TQ-12; Secondary: tinnitus burden, depression tendency, stress experience and self-efficacy measured by PHQ-9, PSQ20, SWOP-K9 | |
7 | somnio | Mental disorder / insomnia | Lorenz et al. (2019) [39] | Ib (RCT) | N = 56 (IG = 29, CG = 27) | Unguided web-based therapy | Waitlist | 12 | Primary: insomnia severity measured by ISI, APSQ, SRBQ; Secondary: depression symptomatology, anxiety symptomatology, somatisation measured by BDI-II, BSI-Somatization | |
8 | velibra | Mental disorder / panic and anxiety disorders | Berger et al. (2017) [40] | Ib (RCT) | N = 139 (IG = 70, CG = 69) | Unguided web-based-based cognitive–behavioural treatment (velibra) | Waitlist | 6 | Primary: disorder unspecific measures of anxiety, depressive symptoms, tension/stress measured by DASS-21, BAI, BDI-II; general psychopathology measured by BSI; quality of life measured by SF-12; Secondary: disorder-specific measures of anxiety measured by SPS, SIAS, ACQ, BSQ, Mobility Inventory for Agoraphobia, PSWQ, CSQ-8 | Reduction of therapy-related expenses and burdens for patients and their relatives |
9 | Vivira | Muscles, bones and joints / koxarthrosis | In publication process | Ib (RCT) | N = 213 | Mobile-app “Vivira”; therapeutic home exercise programme | Physiotherapeutic treatment, home exercise instruction | 3 | Primary: reduction of back pain measured by VNRS; Secondary: quality of life measured by SF-36 | |
10 | vorvida | Mental disorder / mental and behavioral disorders caused by alcohol | Ib (RCT) | N = 608 (IG = 306, CG = 302) | Unguided web-based intervention (vorvida) | Waitlist | 6 | Primary: alcohol consumption measured by QFI, TFB; Secondary: drinking behaviour (binge drinking, drunkenness) measured by Binge drinking, Drunkenness | Patient sovereignty |